DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) ... ( CUPERTINO Calif. Aug. 27 /- DUREC...)

HOME >> MEDICINE >> NEWS

DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology

Date:8/27/2008

CUPERTINO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics (Nasdaq: PTIE), its licensee, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid pain drug candidate based on DURECT's patented ORADUR(TM) technology. This is the third ORADUR-based opioid drug candidate covered by DURECT's collaboration with Pain Therapeutics, for which King Pharmaceuticals (NYSE: KG) holds the commercialization rights. Pain Therapeutics and King Pharmaceuticals have stated that they expect to announce shortly the initiation of a clinical study with this new investigational drug candidate.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"We are very pleased with the progress and speed with which Pain Therapeutics and King Pharmaceuticals are developing this series of four opioids licensed from us," stated James Brown, Chief Executive Officer of DURECT. "This marks another milestone for our ORADUR technology as a versatile platform that provides for the controlled delivery of pharmaceuticals that are commonly abused."

This new drug candidate is the third ORADUR-based opioid drug to enter development. The first drug candidate, REMOXY(R) (ORADUR-based oxycodone), submitted a New Drug Application with the FDA on June 10, 2008 and has been granted Priority Review Designation by the F
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
2. DURECT to Present at UBS Global Life Sciences Conference
3. DURECT to Present at 2007 BIO Investor Forum
4. DURECT to Present at BIO CEO Investor Conference 2008
5. DURECT to Participate in Susquehanna Financial Healthcare Conference
6. DURECT to Participate in Cowen Annual Healthcare Conference
7. DURECT Provides Update on CHRONOGESIC(R) Research Program
8. DURECT to Participate in Morgan Stanley Global Healthcare Conference
9. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
10. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
11. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call

Post Your Comments:

DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) ...( CUPERTINO Calif. Aug. 27 /- DUREC...),Health